TRCT
NVO

Tower Research Capital (TRC)’s Novo Nordisk NVO Stock Holding History

Tower Research Capital (TRC)’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.18M Buy
+32,014
New +$1.52M 0.03% 477
2025
Q4 		– Sell
-1,767
Closed -$98.1K – 5453
2025
Q3 		$98.1K Sell
1,767
-141,474
-99% -$8.28M ﹤0.01% 2007
2025
Q2 		$9.89M Buy
143,241
+134,532
+1,545% +$9.15M 0.27% 63
2025
Q1 		$605K Sell
8,709
-3,912
-31% -$323K 0.02% 728
2024
Q4 		$1.09M Buy
12,621
+2,688
+27% +$291K 0.02% 585
2024
Q3 		$1.18M Sell
9,933
-7,089
-42% -$945K 0.03% 467
2024
Q2 		$2.43M Buy
17,022
+8,060
+90% +$1.07M 0.04% 369
2024
Q1 		$1.15M Buy
8,962
+5,005
+126% +$596K 0.03% 459
2023
Q4 		$409K Buy
3,957
+1,900
+92% +$188K 0.01% 1536
2023
Q3 		$187K Sell
2,057
-1,573
-43% -$139K 0.01% 1473
2023
Q2 		$294K Buy
3,630
+3,232
+812% +$264K 0.01% 1311
2023
Q1 		$32K Buy
398
+248
+165% +$17.6K ﹤0.01% 2928
2022
Q4 		$10K Sell
150
-15,662
-99% -$918K ﹤0.01% 4042
2022
Q3 		$788K Buy
15,812
+7,676
+94% +$411K 0.01% 817
2022
Q2 		$453K Buy
8,136
+956
+13% +$53K 0.01% 1199
2022
Q1 		$398K Sell
7,180
-11,476
-62% -$589K ﹤0.01% 1285
2021
Q4 		$1.04M Buy
18,656
+18,590
+28,167% +$1.01M 0.02% 677
2021
Q3 		$3K Buy
+66
New +$3.19K ﹤0.01% 5124
2021
Q2 		– Sell
-11,260
Closed -$380K – 5727
2021
Q1 		$380K Buy
11,260
+3,602
+47% +$128K 0.01% 1469
2020
Q4 		$267K Sell
7,658
-714
-9% -$24.7K 0.01% 1481
2020
Q3 		$291K Buy
8,372
+7,952
+1,893% +$265K ﹤0.01% 2215
2020
Q2 		$14K Sell
420
-40
-9% -$1.28K ﹤0.01% 3873
2020
Q1 		$14K Buy
+460
New +$13.7K ﹤0.01% 1882
2019
Q4 		– Sell
-706
Closed -$18K – 4123
2019
Q3 		$18K Buy
+706
New +$17.9K ﹤0.01% 2539
2019
Q2 		– Sell
-5,164
Closed -$135K – 4095
2019
Q1 		$135K Buy
5,164
+5,128
+14,244% +$126K 0.01% 1299
2018
Q4 		$1K Buy
+36
New +$800 ﹤0.01% 3632
2018
Q2 		– Sell
-708
Closed -$17K – 3931
2018
Q1 		$17K Buy
+708
New +$18.6K ﹤0.01% 2252
2017
Q4 		– Sell
-2,868
Closed -$69K – 3846
2017
Q3 		$69K Sell
2,868
-1,582
-36% -$35.7K 0.01% 1693
2017
Q2 		$96K Sell
4,450
-1,672
-27% -$33.7K 0.01% 512
2017
Q1 		$105K Buy
6,122
+3,836
+168% +$66.8K 0.01% 455
2016
Q4 		$41K Buy
2,286
+1,782
+354% +$32.3K ﹤0.01% 1559
2016
Q3 		$10K Sell
504
-5,692
-92% -$141K ﹤0.01% 2066
2016
Q2 		$167K Buy
6,196
+5,996
+2,998% +$164K 0.02% 776
2016
Q1 		$5K Hold
200
– – ﹤0.01% 2708
2015
Q4 		$6K Sell
200
-1,750
-90% -$48.4K ﹤0.01% 2793
2015
Q3 		$53K Buy
+1,950
New +$55.2K 0.01% 976
2015
Q2 		– Sell
-4,030
Closed -$108K – 4835
2015
Q1 		$108K Buy
4,030
+3,504
+666% +$80.7K 0.01% 819
2014
Q4 		$11K Buy
526
+326
+163% +$7.28K ﹤0.01% 2073
2014
Q3 		$5K Buy
200
+148
+285% +$3.41K ﹤0.01% 3299
2014
Q2 		$1K Sell
52
-2,614
-98% -$57.7K ﹤0.01% 3714
2014
Q1 		$61K Sell
2,666
-6,144
-70% -$131K 0.01% 952
2013
Q4 		$163K Buy
8,810
+5,190
+143% +$90.4K 0.03% 613
2013
Q3 		$61K Buy
3,620
+2,140
+145% +$36K 0.01% 1735
2013
Q2 		$23K Buy
+1,480
New +$24.6K ﹤0.01% 1576

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Tower Research Capital (TRC)'s NVO Position: Q1 2026 in Review

Tower Research Capital (TRC) opened a new position in Novo Nordisk (NVO) in Q1 2026: 32,014 shares worth $1.18M. The stake represents 0.03% of the portfolio and ranks #477 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in NVO as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in NVO in Q2 2013 and has held it in 44 quarters since. The position peaked at $9.89M in Q2 2025. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Tower Research Capital (TRC) held 32,014 shares of Novo Nordisk worth $1.18M as of Q1 2026.
  • Novo Nordisk was a new Tower Research Capital (TRC) position in Q1 2026.
  • Novo Nordisk made up 0.03% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #477 holding.
  • Tower Research Capital (TRC) first reported a position in Novo Nordisk in Q2 2013 and has held it in 44 quarters since.
  • Tower Research Capital (TRC)'s Novo Nordisk position peaked at $9.89M in Q2 2025.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.